Clinical Trial Detail

NCT ID NCT01966445
Title Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements no
Sponsors GlaxoSmithKline
Indications

head and neck squamous cell carcinoma

hepatocellular carcinoma

breast cancer

prostate cancer

parotid gland cancer

nasopharynx carcinoma

urinary bladder cancer

melanoma

ovarian cancer

pancreatic cancer

colorectal cancer

cervical cancer

lung non-small cell carcinoma

Therapies

GSK2849330

Age Groups: adult

No variant requirements are available.